Spain’s National Commission of Markets and Competition (CNMC) last year doubled the sanctions against companies for damages against free competition. The body chaired by José María Marín Quemada has imposed fines for almost €225 million (US$256.4 million), compared to €138 million (US$157.3 million) collected the previous year. This is the second heaviest exercise in fines by the CNMC for practices against free competition since Marín Quemada arrived, after breaking all the records in 2015.
The increase, which reverses two years of decrease in the amount collected, is mainly due to two specific cases: The first, the four large Spanish banks, sanctioned in February with a total of €91 million (US$103.7 million) “to be arranged for offer interest rate derivatives under conditions different from those agreed with customers, in which it was specified that they would be contracted under “market conditions.”
The second important case is the sanction to the parcel industry, imposed in March. The CNMC fined nearly ten million parcel companies with almost €70 million euros (US$79.8 million) for dividing the customers among themselves.
Full Content: OK Diario
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan